Navigation Links
New insights into limb formation
Date:8/12/2009

LA JOLLA, Calif., August 12, 2009 -- Investigators at Burnham Institute for Medical Research (Burnham) and the University of Connecticut Health Center (U.C.H.C.) have gained new understanding of the role hyaluronic acid (HA) plays in skeletal growth, chondrocyte maturation and joint formation in developing limbs. Significantly, these discoveries were made using a novel mouse model in which the production of HA is blocked in a tissue-specific manner. The Yamaguchi laboratory genetically modified the Has2 gene, which is a critical enzyme for HA synthesis, so that the gene can be "conditionally" disrupted in mice. This is the first time a conditional Has2 knockout mouse has been created, a breakthrough that opens vast possibilities for future research. The paper was published online in the journal Development on July 24.

HA is a large sugar molecule that is produced by every cell in the body and has been thought to play a role in joint disease, heart disease and invasive cancers. Yu Yamaguchi, M.D., Ph.D., a professor in the Sanford Children's Health Research Center at Burnham and Robert Kosher, Ph.D., a professor in the Center for Regenerative Medicine and Skeletal Development at U.C.H.C. and colleagues showed that transgenic mice, in which Has2 was inactivated in the limb bud mesoderm, had shortened limbs, abnormal growth plates and duplicated bones in the fingers and toes.

"Because hyaluronic acid is so prevalent in the body, it has been difficult to study," said Dr. Yamaguchi. "Systemic Has2 knockout mice died mid-gestation and could not be used to study the role of HA in adults. By inactivating Has2 in specific tissues, we give ourselves the opportunity to study the many roles HA plays in biology. This mouse model will be useful to study the role of HA in various age-related diseases and conditions, such as arthritis and skin aging, as well as cancer."

To create the conditional knockout mice, the Yamaguchi laboratory genetically engineered the Has2 gene to create the Has2flox allele. The team then added the Prxl1-Cre transgene, which is associated with early limb bud mesenchyme to produce the conditional Has2 knockout mice.


'/>"/>

Contact: Josh Baxt
jbaxt@burnham.org
858-795-5236
Burnham Institute
Source:Eurekalert

Related biology news :

1. New insights into health and environmental effects of carbon nanoparticles
2. UC San Diego engineer provides insights to decades-old DNA squabble
3. Tumor suppressor gene in flies may provide insights for human brain tumors
4. Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution
5. Slicing chromosomes leads to new insights into cell division
6. Researchers gain genome-wide insights into patterns of the worlds human population structures
7. Limping rat provides sciatica insights
8. First neuroimaging study examining motor execution in children with autism reveals new insights
9. New insights into progressive hearing loss
10. Lohafex provides new insights on plankton ecology
11. Addiction: Insights from Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology: